Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results

February 21, 2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

“We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome,” said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. “We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013.”

Key Developments in 2012

  • LX4211: Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reductions in body weight and blood pressure. In addition, Lexicon initiated a study in type 2 diabetes patients with renal impairment.
  • Telotristat etiprate (LX1032): Lexicon initiated a pivotal Phase 3 clinical trial of telotristat etiprate, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels. The Phase 3 registrational trial is a 12-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of telotristat etiprate as a new treatment for carcinoid syndrome that is refractory to current therapy. The study is expected to enroll approximately 105 patients. Lexicon reported data from an open-label Phase 2 trial in which telotristat etiprate showed evidence of clinical benefit across several endpoints in carcinoid syndrome patients. Benefits included reductions in bowel movement frequency, decreased urinary 5-HIAA (a biomarker of serotonin synthesis), and improvements in patient-reported relief of symptoms. Lexicon received Orphan Drug designation for telotristat etiprate from the U.S. Food and Drug Administration (FDA) for the treatment of carcinoid syndrome, having previously obtained Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA). In addition to ongoing development in carcinoid syndrome, Lexicon also initiated a Phase 2 proof-of-concept study of telotristat etiprate in patients with ulcerative colitis.
  • LX1033: Lexicon initiated a Phase 2 clinical trial of LX1033, an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract to reduce serotonin production, in patients with diarrhea-predominant IBS (IBS-d). The Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of LX1033 in approximately 360 IBS-d patients. Lexicon also received Fast Track status from the FDA for the development of LX1033 in IBS-d.
  • Other Programs: Lexicon obtained results from Phase 1 studies of LX2931, an inhibitor of sphingosine-1-phosphate lyase, in patients with rheumatoid arthritis, and LX7101, an inhibitor of LIM domain kinase 2 (LIMK2), in patients with glaucoma. Both compounds were well-tolerated and showed signals of clinical benefit in the respective studies.

Financial Results

Revenues: Lexicon’s revenues for the three months ended December 31, 2012 decreased 36 percent to $0.2 million from $0.3 million for the corresponding period in 2011. For the year ended December 31, 2012, revenues decreased 41 percent to $1.1 million from $1.8 million for the corresponding period in 2011.

Research and Development Expenses: Research and development expenses for the three months ended December 31, 2012 decreased 25 percent to $21.0 million from $28.1 million for the corresponding period in 2011, primarily due to a decrease in external manufacturing, clinical research and development costs. For the year ended December 31, 2012, research and development expenses decreased 10 percent to $82.6 million from $91.8 million for the corresponding period in 2011.

Increase (Decrease) in Fair Value of Symphony Icon Purchase Liability: In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon’s consolidated statements of operations. For the three months ended December 31, 2012, the fair value of the Symphony Icon purchase liability decreased by $0.2 million, compared to an increase of $1.6 million in the corresponding period in 2011. For the years ended December 31, 2012 and 2011, the increase in fair value of the Symphony Icon purchase liability was $9.9 million and $6.8 million, respectively.

General and Administrative Expenses: General and administrative expenses for the three months ended December 31, 2012 decreased two percent to $3.9 million from $4.0 million for the corresponding period in 2011. For the year ended December 31, 2012, general and administrative expenses decreased two percent to $17.0 million from $17.4 million for the corresponding period in 2011.

Consolidated Net Loss: Net loss for the three months ended December 31, 2012 was $24.9 million, or $0.05 per share, compared to a net loss of $33.8 million, or $0.10 per share, in the corresponding period in 2011. Net loss for the year ended December 31, 2012 was $110.2 million, or $0.23 per share, compared to a net loss of $116.2 million, or $0.34 per share, for the corresponding period in 2011. For the three months and year ended December 31, 2012, net loss included non-cash, stock-based compensation expense of $1.6 million and $6.5 million, respectively. For the three months and year ended December 31, 2011, net loss included non-cash, stock-based compensation expense of $1.4 million and $5.7 million, respectively.

Cash and Investments: As of December 31, 2012, Lexicon had $223.2 million in cash and investments, as compared to cash and investments of $206.8 million as of September 30, 2012 and $281.7 million as of December 31, 2011.

Lexicon Conference Call
Lexicon management will hold a conference call to discuss its clinical development progress and financial results for 2012 and financial guidance for 2013 at 11:00 a.m. Eastern Time on February 21, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 12316846. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through March 21, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon’s research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements”, including statements relating to Lexicon’s clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101. In addition, this press release also contains forward-looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

               Lexicon Pharmaceuticals, Inc.
                  Selected Financial Data

    Consolidated Statements of
     Operations Data                            Three Months Ended                 Year Ended
                                                   December 31,                   December 31,
                                                   ------------                   ------------
    (In thousands, except per share
     data)                                          2012               2011                 2012       2011
                                             (unaudited)                     (unaudited)
    Revenues:
            Collaborative research                  $218               $320                 $783     $1,632
            Subscription and license fees              -                 23                  306        217
                                                     ---                ---                  ---        ---
                   Total revenues                    218                343                1,089      1,849
    Operating expenses:
    Research and development, including
     stock-based compensation                     20,990             28,107               82,574     91,828
    of $798, $769, $3,673 and $3,249,
     respectively
    Increase (decrease) in fair value of
     Symphony Icon, Inc                             (200)             1,568                9,887      6,766
    purchase liability
    General and administrative,
     including stock-based compensation            3,920              4,010               17,043     17,350
    of $792, $584, $2,822 and $2,458,
     respectively

                   Total operating expenses       24,710             33,685              109,504    115,944
                                                  ------             ------              -------    -------
    Loss from operations                         (24,492)           (33,342)            (108,415)  (114,095)
    Interest income                                   55                 40                  213        255
    Interest expense                                (520)              (551)              (2,114)    (2,528)
    Other income, net                                 84                  8                  105        153
                                                     ---                ---                  ---        ---
    Consolidated net loss                       $(24,873)          $(33,845)           $(110,211) $(116,215)
                                                ========           ========            =========  =========

    Consolidated net loss per common
     share, basic and diluted                     $(0.05)            $(0.10)              $(0.23)    $(0.34)
                                                  ======             ======               ======     ======

    Shares used in computing
     consolidated net loss per common
     share, basic and diluted                    507,619            350,069              489,707    340,761

    Consolidated Balance Sheet
     Data                       As of December 31,         As of December 31,
    (In thousands)                                   2012                      2011
                                                     ----                      ----
                                    (unaudited)
    Cash and investments                         $223,208                  $281,692
    Property and equipment, net                    42,634                    46,417
    Goodwill                                       44,543                    44,543
    Other intangible assets                        53,557                    53,557
    Total assets                                  371,778                   430,512
    Deferred revenue                               14,038                    14,331
    Current and long-term debt                     23,451                    24,894
    Other long-term liabilities                    32,283                    55,146
    Accumulated deficit                          (899,832)                 (789,621)
    Total stockholders' equity                    266,678                   297,568

SOURCE Lexicon Pharmaceuticals, Inc.


Source: PR Newswire